Literature DB >> 29103998

TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.

Mahyar Nouri-Shirazi1, Saba Tamjidi2, Erika Nourishirazi2, Elisabeth Guinet2.   

Abstract

BACKGROUND: Most current prophylactic vaccines confer protection primarily through humoral immunity. Indeed, aluminum salts which have been widely used as adjuvants in vaccines primarily enhance Th2-driven antibody responses. Therefore, new vaccines formulation is moving toward a careful selection of adjuvants that also elicit significant Th1 or Tc1 responses. Several TLR agonists have been tested as potential new adjuvants in clinical and preclinical studies with some efficacy. These studies suggest that combining more than one of TLR ligands enhances the magnitude of immune responses to cancer and infectious disease.
OBJECTIVES: In order to evaluate the synergistic effect of TLR agonists for effective induction of cellular immunity, we investigated the effects of single and/or combined TLR agonists on monocyte-derived DC maturation, DC-NK crosstalk and ultimately naïve T cells polarization into effector T cells.
RESULTS: Among the adjuvants tested, we found that TLR3, TLR4, TLR7/8 and TLR8 agonists were the most effective adjuvants to increase the expression levels of antigen-presenting, co-stimulatory molecules and production of cytokines by maturing DCs. When combined, TLR3+8 and TLR4+8 synergistically optimized DC maturation and IFN-γ secretion from NK cells co-cultured with DCs. Interestingly, co-culture of DC-NK-T treated with aluminum salt produced the highest percentage of effector memory CFSE-CCR7- Th1 cells whereas TLR3+8 and TLR4+8 treated co-cultures produced the highest percentage of effector memory CFSE-CCR7- Tc1 cells producing IFN-γ. Finally, while both TLR3+8 or TLR4+8 treated co-cultures generated similar frequency of Th1 and Tc1 effector cells, the effector cells from the latter co-culture produced quantitatively more IFN-γ in the supernatant.
CONCLUSION: Our data indicate that if in need of an enhanced DC-NK mediated cellular immunity one may select TLR agonists with defined synergistic effects.
Copyright © 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DC-NK crosstalk; Dendritic cells; NK cells; TLR agonists; Tc1; Th1

Mesh:

Substances:

Year:  2017        PMID: 29103998      PMCID: PMC5744900          DOI: 10.1016/j.imlet.2017.10.015

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  45 in total

1.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells.

Authors:  A Langenkamp; M Messi; A Lanzavecchia; F Sallusto
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

2.  Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.

Authors:  Stefani Spranger; Miran Javorovic; Maja Bürdek; Susanne Wilde; Barbara Mosetter; Stefanie Tippmer; Iris Bigalke; Christiane Geiger; Dolores J Schendel; Bernhard Frankenberger
Journal:  J Immunol       Date:  2010-05-28       Impact factor: 5.422

3.  Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells.

Authors:  Doreen Krumbiegel; Fred Zepp; Claudius Ullrich Meyer
Journal:  Hum Immunol       Date:  2007-08-29       Impact factor: 2.850

Review 4.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Immunity       Date:  2011-05-27       Impact factor: 31.745

5.  NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion.

Authors:  Barbara Morandi; Gwenola Bougras; William A Muller; Guido Ferlazzo; Christian Münz
Journal:  Eur J Immunol       Date:  2006-09       Impact factor: 5.532

6.  Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

Authors:  Keith B Gorden; Kevin S Gorski; Sheila J Gibson; Ross M Kedl; William C Kieper; Xiaohong Qiu; Mark A Tomai; Sefik S Alkan; John P Vasilakos
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

7.  NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection.

Authors:  Monia Draghi; Achal Pashine; Bharati Sanjanwala; Ketevan Gendzekhadze; Claudia Cantoni; David Cosman; Alessandro Moretta; Nicholas M Valiante; Peter Parham
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

8.  Effect of multiple activation stimuli on the generation of Th1-polarizing dendritic cells.

Authors:  Christopher Paustian; Richard Caspell; Terrence Johnson; Peter A Cohen; Suyu Shu; Shuwen Xu; Brian J Czerniecki; Gary K Koski
Journal:  Hum Immunol       Date:  2010-10-15       Impact factor: 2.850

Review 9.  Vaccine adjuvants: putting innate immunity to work.

Authors:  Robert L Coffman; Alan Sher; Robert A Seder
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

Review 10.  Toll-like receptors. II. Distribution and pathways involved in TLR signalling.

Authors:  F Sandor; M Buc
Journal:  Folia Biol (Praha)       Date:  2005       Impact factor: 0.906

View more
  10 in total

1.  Combination of TLR8 and TLR4 agonists reduces the degrading effects of nicotine on DC-NK mediated effector T cell generation.

Authors:  Mahyar Nouri-Shirazi; Saba Tamjidi; Erika Nourishirazi; Elisabeth Guinet
Journal:  Int Immunopharmacol       Date:  2018-05-24       Impact factor: 4.932

Review 2.  The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy.

Authors:  Lingling Huang; Xiaoyan Ge; Yang Liu; Hui Li; Zhiyue Zhang
Journal:  Pharmaceutics       Date:  2022-06-10       Impact factor: 6.525

Review 3.  Synergistic Activation of Toll-Like and NOD Receptors by Complementary Antigens as Facilitators of Autoimmune Disease: Review, Model and Novel Predictions.

Authors:  Robert Root-Bernstein
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

4.  Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.

Authors:  Mansi Saxena; Rachel L Sabado; Melissa La Mar; Hiroshi Mohri; Andres M Salazar; Hanqing Dong; Joel Correa Da Rosa; Martin Markowitz; Nina Bhardwaj; Elizabeth Miller
Journal:  Front Immunol       Date:  2019-04-09       Impact factor: 7.561

Review 5.  RNA Sensing of Mycobacterium tuberculosis and Its Impact on TB Vaccination Strategies.

Authors:  Sanne Burkert; Ralf R Schumann
Journal:  Vaccines (Basel)       Date:  2020-02-04

6.  Toll-Like Receptor-Mediated Activation of CD39 Internalization in BMDCs Leads to Extracellular ATP Accumulation and Facilitates P2X7 Receptor Activation.

Authors:  Ronglan Zhao; Jinjuan Qiao; Xumei Zhang; Yansong Zhao; Xiangying Meng; Deming Sun; Xiaoxiang Peng
Journal:  Front Immunol       Date:  2019-10-31       Impact factor: 7.561

7.  The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration.

Authors:  Christoph M Janitzek; Philip H R Carlsen; Susan Thrane; Vijansh M Khanna; Virginie Jakob; Christophe Barnier-Quer; Nicolas Collin; Thor G Theander; Ali Salanti; Morten A Nielsen; Adam F Sander
Journal:  Vaccines (Basel)       Date:  2021-02-06

8.  Human lung cDC1 drive increased perforin-mediated NK cytotoxicity in chronic obstructive pulmonary disease.

Authors:  Alexander M Pallazola; Jessica X Rao; Dawit T Mengistu; Maria S Morcos; Mariam S Toma; Valerie R Stolberg; Alexandra Tretyakova; Lisa McCloskey; Jeffrey L Curtis; Christine M Freeman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-10-27       Impact factor: 6.011

9.  Dendritic cells pulsed with placental gp96 promote tumor-reactive immune responses.

Authors:  Huaguo Zheng; Lanlan Liu; Han Zhang; Fangming Kan; Shuo Wang; Yang Li; Huaqin Tian; Songdong Meng
Journal:  PLoS One       Date:  2019-01-31       Impact factor: 3.240

Review 10.  The impact of immuno-aging on SARS-CoV-2 vaccine development.

Authors:  Jennifer Connors; Matthew R Bell; Jennifer Marcy; Michele Kutzler; Elias K Haddad
Journal:  Geroscience       Date:  2021-02-11       Impact factor: 7.713

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.